Targeting DNA polymerase ß for therapeutic intervention

Eva M Goellner1, David Svilar, Karen H Almeida

  • 1Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213-1863, USA.

Insights

DNA polymerase ß (Polß) is crucial for DNA repair and cancer development. Targeting Polß with inhibitors could enhance cancer treatments, but its complex role requires careful therapeutic strategies for effectiveness and safety.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry
  • Cancer Research

Background:

  • DNA damage is a key factor in diseases like cancer, diabetes, and neurodegeneration.
  • DNA repair proteins maintain genome integrity, potentially reducing disease onset.
  • DNA polymerase ß (Polß) is central to base excision repair and involved in genome maintenance, oncogenic transformation, and cellular responses to stress and genotoxicants.

Purpose of the Study:

  • To explore the therapeutic potential of DNA polymerase ß (Polß) inhibitors in cancer treatment.
  • To address the challenges in developing specific Polß inhibitors due to its complex regulatory roles.
  • To review existing small molecule inhibitors and discuss novel inhibition strategies for Polß.

Main Methods:

  • Summary of reported small molecule inhibitors of Polß.
  • Discussion of genetic, biochemical, and chemical studies relevant to Polß inhibition.
  • Exploration of potential inhibitor combinatorial approaches and tumor specificity.

Main Results:

  • Polß's multifaceted role in DNA metabolism complicates the development of targeted inhibitors.
  • Multiple enzymatic activities, binding partners, and post-translational modifications offer various inhibition opportunities.
  • Existing research highlights diverse approaches to targeting Polß for therapeutic intervention.

Conclusions:

  • Polß inhibitors show promise for improving chemotherapy and radiation response in cancer.
  • Overcoming Polß's complex regulation is key to developing effective and safe inhibitors.
  • Further research into combinatorial strategies and tumor-specific targeting is warranted for successful therapeutic application.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Translesion DNA Polymerases02:10

Translesion DNA Polymerases

Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...